» Articles » PMID: 35186771

Immune Infiltration Associated MAN2B1 Is a Novel Prognostic Biomarker for Glioma

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Feb 21
PMID 35186771
Authors
Affiliations
Soon will be listed here.
Abstract

Mannosidase Alpha Class 2B Member 1 (MAN2B1) gene encodes lysosomal alpha-d-mannosidase involved in the ordered degradation of N-linked glycoproteins. Alteration in MAN2B1 has been proved to be accountable for several diseases. However, the relationship between MAN2B1 and glioma malignancy remains unclear. In this study, RNA-seq data from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas datasets were analyzed to explore the correlation between MAN2B1 and clinicopathological features, prognosis, and somatic mutations in gliomas. We found that MAN2B1 was elevated in glioma and was correlated with malignant clinical and molecular features. Upregulated expression of MAN2B1 is prognostic for poor outcomes in glioma patients. Different frequencies of somatic mutations were found in gliomas between high and low MAN2B1 expression. Real-time quantitative polymerase chain reaction, western blot, and immunohistochemistry staining from glioma patient samples and cell lines were used to validate bioinformatic findings. Functional enrichment analysis showed that MAN2B1 was involved in immune and inflammation processes. Moreover, MAN2B1 expression was strongly correlated with M2 macrophages and weakly correlated with M1 macrophages. Further analysis confirmed that MAN2B1 was closely associated with the markers of M2 macrophages and tumor-associated macrophages. Taken together, MAN2B1 is a potential prognostic biomarker in glioma and associates with immune infiltration.

Citing Articles

MAN2B1 in immune system-related diseases, neurodegenerative disorders and cancers: functions beyond α-mannosidosis.

Han Y, Zhou Y, Pan J, Sun M, Yang J Expert Rev Mol Med. 2024; 27():e4.

PMID: 39628046 PMC: 11707832. DOI: 10.1017/erm.2024.34.


Oncological Aspects of Lysosomal Storage Diseases.

Lugowska A Cells. 2024; 13(19.

PMID: 39404425 PMC: 11475748. DOI: 10.3390/cells13191664.


Multi-proteomic analyses of 5xFAD mice reveal new molecular signatures of early-stage Alzheimer's disease.

Lee S, Jang K, Lee H, Jo Y, Kwon D, Park G Aging Cell. 2024; 23(6):e14137.

PMID: 38436501 PMC: 11166370. DOI: 10.1111/acel.14137.


Genetics of enzymatic dysfunctions in metabolic disorders and cancer.

Mahe M, Rios-Fuller T, Karolin A, Schneider R Front Oncol. 2023; 13:1230934.

PMID: 37601653 PMC: 10433910. DOI: 10.3389/fonc.2023.1230934.


GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.

Xu S, Xiao H, Hu Z, Zhong X, Zeng Y, Wu Y Front Oncol. 2023; 13:1162983.

PMID: 37091137 PMC: 10117795. DOI: 10.3389/fonc.2023.1162983.

References
1.
Baxevanis C, Fortis S, Perez S . The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2019; 72:76-89. DOI: 10.1016/j.semcancer.2019.12.018. View

2.
Carpelan-Holmstrom M, Louhimo J, Stenman U, Alfthan H, Haglund C . CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002; 22(4):2311-6. View

3.
Drake R, Jones E, Powers T, Nyalwidhe J . Altered glycosylation in prostate cancer. Adv Cancer Res. 2015; 126:345-82. DOI: 10.1016/bs.acr.2014.12.001. View

4.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J . Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010; 70(14):5728-39. DOI: 10.1158/0008-5472.CAN-09-4672. View

5.
Moreira D, Sampath S, Won H, White S, Su Y, Alcantara M . Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity. J Clin Invest. 2020; 131(2). PMC: 7810478. DOI: 10.1172/JCI137001. View